Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, August 31st:
Rexahn Pharmaceuticals, Inc. : This clinical stage biopharmaceutical company has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings advancing 9.5% over the last 60 days.
Rexahn Pharmaceuticals' shares gained 13.9% over the last one month higher than the S&P 500’s increase of 3%. The company possesses a Momentum Score of A.
The E.W. Scripps Company (SSP - Free Report) : This media enterprise has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings rising 15.3% over the last 60 days.
E.W. Scripps' shares gained 11.7% over the last one month. The company possesses a Momentum Score of A.
Sesen Bio, Inc. : This late-stage clinical company has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings advancing 18.8% over the last 60 days.
Sesen Bio's shares gained 17.1% over the last one month. The company possesses a Momentum Score of A.
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.
5 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2018 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs. A bonus Zacks Special Report names this breakthrough and the 5 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains.
Click to see them right now >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, August 31st:
Rexahn Pharmaceuticals, Inc. : This clinical stage biopharmaceutical company has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings advancing 9.5% over the last 60 days.
Rexahn Pharmaceuticals' shares gained 13.9% over the last one month higher than the S&P 500’s increase of 3%. The company possesses a Momentum Score of A.
The E.W. Scripps Company (SSP - Free Report) : This media enterprise has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings rising 15.3% over the last 60 days.
E.W. Scripps' shares gained 11.7% over the last one month. The company possesses a Momentum Score of A.
Sesen Bio, Inc. : This late-stage clinical company has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings advancing 18.8% over the last 60 days.
Sesen Bio's shares gained 17.1% over the last one month. The company possesses a Momentum Score of A.
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.
5 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2018 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs. A bonus Zacks Special Report names this breakthrough and the 5 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains.
Click to see them right now >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on SSP - FREE